Unibest is pleased to release its updated Finished Dosage Form (FDF) pipeline as of Q3 2025. The portfolio encompasses a diverse range of therapeutic areas including cardiovascular, metabolic, oncology, and central nervous system disorders.

Our FDF assets are available for out-licensing to qualified partners globally. Each asset comes with a comprehensive regulatory dossier, CMC documentation, and market access strategy tailored to the target region.

Key highlights of the 2025 FDF pipeline include three assets with completed Phase III trials in Greater China, four products holding EU-approved reference drug status, and two novel formulations offering significant bioavailability advantages over existing standards of care.

Unibest's licensing team is available to arrange one-on-one meetings at upcoming industry conferences, including BIO International, CPhI Worldwide, and JP Morgan Healthcare Conference. Partnering inquiries can be directed to bd@unibestcn.com.